메뉴 건너뛰기




Volumn 6, Issue 4, 2013, Pages 168-177

Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: Qualitative synthesis of scientific evidence;Coste-efectividad del tratamiento farmacológico del trastorno por déficit de atención e hiperactividad en niños y adolescentes: síntesis cualitativa de la evidencia científica

Author keywords

Attention deficit hyperactivity disorder; Children and adolescents; Cost effectiveness; Hyperactivity; Systematic review

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO;

EID: 84887318031     PISSN: 18889891     EISSN: 19894600     Source Type: Journal    
DOI: 10.1016/j.rpsm.2012.12.002     Document Type: Article
Times cited : (14)

References (29)
  • 1
    • 84887320030 scopus 로고    scopus 로고
    • Grupo de trabajo de la Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Fundació Sant Joan de Déu, coordinador. Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Agència d'Informació, Avaluació i Qualitat (AIAQS) de Cataluña; 2010. Guías de Práctica Clínica en el SNS: AATRM N. 2007/18
    • Grupo de trabajo de la Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Fundació Sant Joan de Déu, coordinador. Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Agència d'Informació, Avaluació i Qualitat (AIAQS) de Cataluña; 2010. Guías de Práctica Clínica en el SNS: AATRM N. 2007/18.
  • 2
    • 84871732249 scopus 로고    scopus 로고
    • Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: A systematic review and meta-analysis of epidemiological studies
    • F. Catalá-López, S. Peiró, M. Ridao, G. Sanfélix-Gimeno, R. Gènova-Maleras, and M.A. Catalá Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies BMC Psychiatry 12 2012 168
    • (2012) BMC Psychiatry , vol.12 , pp. 168
    • Catalá-López, F.1    Peiró, S.2    Ridao, M.3    Sanfélix-Gimeno, G.4    Gènova-Maleras, R.5    Catalá, M.A.6
  • 5
    • 79952226742 scopus 로고    scopus 로고
    • Evaluación económica sobre enfermedades neurológicas y mentales en España: Revisión sistemática y análisis comparativo
    • F. Catalá-López, A. García-Altés, E. Álvarez-Martín, R. Gènova-Maleras, and C. Morant-Ginestar Evaluación económica sobre enfermedades neurológicas y mentales en España: revisión sistemática y análisis comparativo Rev Neurol 52 2011 65 71
    • (2011) Rev Neurol , vol.52 , pp. 65-71
    • Catalá-López, F.1    García-Altés, A.2    Álvarez-Martín, E.3    Gènova-Maleras, R.4    Morant-Ginestar, C.5
  • 6
    • 79960692954 scopus 로고    scopus 로고
    • Evaluación económica de tecnologías sanitarias: Una introducción para médicos
    • R. Luengo-Fernández, C. Hernández-Quesada, and O. Rivero-Arias Evaluación económica de tecnologías sanitarias: una introducción para médicos Rev Neurol 53 2011 107 115
    • (2011) Rev Neurol , vol.53 , pp. 107-115
    • Luengo-Fernández, R.1    Hernández-Quesada, C.2    Rivero-Arias, O.3
  • 7
    • 80051760784 scopus 로고    scopus 로고
    • To fund or not to fund: Development of a decision-making framework for the coverage of new health technologies
    • T. Stafinski, D. Menon, C. McCabe, and D.J. Philippon To fund or not to fund: development of a decision-making framework for the coverage of new health technologies Pharmacoeconomics 29 2011 771 780
    • (2011) Pharmacoeconomics , vol.29 , pp. 771-780
    • Stafinski, T.1    Menon, D.2    McCabe, C.3    Philippon, D.J.4
  • 9
    • 84887316595 scopus 로고    scopus 로고
    • Atomoxetina (DOE)
    • Centro de información y evaluación de medicamentos y productos sanitarios de la Región de Murcia
    • Centro de información y evaluación de medicamentos y productos sanitarios de la Región de Murcia Atomoxetina (DOE) Evaluación farmacoterapéutica 10 2010 1 4
    • (2010) Evaluación Farmacoterapéutica , vol.10 , pp. 1-4
  • 10
    • 80054885184 scopus 로고    scopus 로고
    • ADHD in children and adolescents, search date August 2009
    • D. Keen, and I. Hadjikoumi ADHD in children and adolescents, search date August 2009 Clin Evidence 2 2011 312
    • (2011) Clin Evidence , vol.2 , pp. 312
    • Keen, D.1    Hadjikoumi, I.2
  • 11
    • 34648837382 scopus 로고    scopus 로고
    • Efficacy and safety of atomoxetine for attention deficit/hyperactivity disorder in children and adolescents-meta-analysis and metaregression analysis
    • J.Y. Cheng, R.Y. Chen, J.S. Ko, and E.M. Ng Efficacy and safety of atomoxetine for attention deficit/hyperactivity disorder in children and adolescents-meta-analysis and metaregression analysis Psychopharmacology 194 2007 197 209
    • (2007) Psychopharmacology , vol.194 , pp. 197-209
    • Cheng, J.Y.1    Chen, R.Y.2    Ko, J.S.3    Ng, E.M.4
  • 12
    • 77956126510 scopus 로고    scopus 로고
    • Scottish Intercollegiate Guidelines Network (SIGN) Scottish Intercollegiate Guidelines Network (SIGN) Edinburgh (Scotland) [consultado 16 Jul 2012]. Disponible en
    • Scottish Intercollegiate Guidelines Network (SIGN) Attention deficit and hyperkinetic disorders in children and young people 2009 Scottish Intercollegiate Guidelines Network (SIGN) Edinburgh (Scotland) [consultado 16 Jul 2012]. Disponible en: http://www.sign.ac.uk/pdf/sign112.pdf
    • (2009) Attention Deficit and Hyperkinetic Disorders in Children and Young People
  • 13
    • 53049088671 scopus 로고    scopus 로고
    • National Institute for Health and Clinical Excellence (NICE) The British Psychological Society and The Royal College of Psychiatrist London, UK [consultado 16 Jul 2012]. Disponible en
    • National Institute for Health and Clinical Excellence (NICE) Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults 2009 The British Psychological Society and The Royal College of Psychiatrist London, UK [consultado 16 Jul 2012]. Disponible en: http://www.nice.org.uk/nicemedia/pdf/ADHDFullGuideline.pdf
    • (2009) Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults
  • 14
    • 34250797891 scopus 로고    scopus 로고
    • Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder
    • S. Pliszka Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 46 2007 894 921
    • (2007) J Am Acad Child Adolesc Psychiatry , vol.46 , pp. 894-921
    • Pliszka, S.1
  • 17
    • 34248149476 scopus 로고    scopus 로고
    • Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, double blind comparison trial
    • Y. Wang, Y. Zheng, Y. Du, D.H. Song, Y.J. Shin, and S.C. Cho Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double blind comparison trial Aust NZ J Psychiatry 41 2007 222 230
    • (2007) Aust NZ J Psychiatry , vol.41 , pp. 222-230
    • Wang, Y.1    Zheng, Y.2    Du, Y.3    Song, D.H.4    Shin, Y.J.5    Cho, S.C.6
  • 18
    • 44949116355 scopus 로고    scopus 로고
    • Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response
    • J.H. Newcorn, C.J. Kratochvil, A.J. Allen, C.D. Casat, D.D. Ruff, and R.J. Moore Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response Am J Psychiatry 165 2008 721 730
    • (2008) Am J Psychiatry , vol.165 , pp. 721-730
    • Newcorn, J.H.1    Kratochvil, C.J.2    Allen, A.J.3    Casat, C.D.4    Ruff, D.D.5    Moore, R.J.6
  • 19
    • 0003568038 scopus 로고    scopus 로고
    • Economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder
    • A. Miller, S.K. Lee, P. Raina, A. Klassen, J. Zupancic, L. Olsen, Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Ottawa
    • J.A.F. Zupancic, A. Miller, P. Raina, S.K. Lee, A. Klassen, and L. Olsen Economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder A. Miller, S.K. Lee, P. Raina, A. Klassen, J. Zupancic, L. Olsen, A review of therapies for attention-deficit/ hyperactivity disorder 1998 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Ottawa
    • (1998) A Review of Therapies for Attention-deficit/hyperactivity Disorder
    • Zupancic, J.A.F.1    Miller, A.2    Raina, P.3    Lee, S.K.4    Klassen, A.5    Olsen, L.6
  • 21
    • 0034960256 scopus 로고    scopus 로고
    • Methylphenidate in children with hiperactivity: Review and cost-utility analysis
    • A. Gilmore, and R. Milne Methylphenidate in children with hiperactivity: review and cost-utility analysis Pharmacoepidemiol Drug Saf 10 2001 85 94
    • (2001) Pharmacoepidemiol Drug Saf , vol.10 , pp. 85-94
    • Gilmore, A.1    Milne, R.2
  • 22
    • 4444262411 scopus 로고    scopus 로고
    • Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder
    • M. Donnelly, M.M. Haby, R. Carter, G. Andrews, and T. Vos Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder Aust N Z J Psychiatry 38 2004 592 601
    • (2004) Aust N Z J Psychiatry , vol.38 , pp. 592-601
    • Donnelly, M.1    Haby, M.M.2    Carter, R.3    Andrews, G.4    Vos, T.5
  • 23
    • 9944247045 scopus 로고    scopus 로고
    • Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD
    • S. Narayan, and J. Hay Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD Expert Rev Pharmacoecon Outcomes Res 4 2004 625 634
    • (2004) Expert Rev Pharmacoecon Outcomes Res , vol.4 , pp. 625-634
    • Narayan, S.1    Hay, J.2
  • 24
    • 33748278913 scopus 로고    scopus 로고
    • A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents
    • iii-iv, xiii-146
    • S. King, S. Griffin, Z. Hodges, H. Weatherly, C. Asseburg, and G. Richardson A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents Health Technol Asses 10 2006 iii-iv, xiii-146
    • (2006) Health Technol Asses , vol.10
    • King, S.1    Griffin, S.2    Hodges, Z.3    Weatherly, H.4    Asseburg, C.5    Richardson, G.6
  • 25
    • 44049084834 scopus 로고    scopus 로고
    • A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom
    • S. Cottrell, D. Tilden, P. Robinson, J. Bae, J. Arellano, and E. Edgell A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom Value Health 11 2008 376 388
    • (2008) Value Health , vol.11 , pp. 376-388
    • Cottrell, S.1    Tilden, D.2    Robinson, P.3    Bae, J.4    Arellano, J.5    Edgell, E.6
  • 26
    • 38149076421 scopus 로고    scopus 로고
    • Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: A study of cost effectiveness in the Netherlands
    • A. Faber, M. van Agthoven, L.J. Kalverdijk, H. Tobi, L.T. de Jong-van den Berg, and L. Annemans Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands CNS Drugs 22 2008 157 170
    • (2008) CNS Drugs , vol.22 , pp. 157-170
    • Faber, A.1    Van Agthoven, M.2    Kalverdijk, L.J.3    Tobi, H.4    De Jong-Van Den Berg, L.T.5    Annemans, L.6
  • 27
    • 65449173644 scopus 로고    scopus 로고
    • A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain
    • J. Hong, T. Dilla, and J. Arellano A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain BMC Psychiatry 9 2009 15
    • (2009) BMC Psychiatry , vol.9 , pp. 15
    • Hong, J.1    Dilla, T.2    Arellano, J.3
  • 28
    • 77955600818 scopus 로고    scopus 로고
    • The pharmaceutical economics of child psychiatric drug treatment
    • M. Schlander The pharmaceutical economics of child psychiatric drug treatment Curr Pharm Des 16 2010 2443 2461
    • (2010) Curr Pharm des , vol.16 , pp. 2443-2461
    • Schlander, M.1
  • 29
    • 84887318186 scopus 로고    scopus 로고
    • Comisión de Evaluación Económica e Impacto Presupuestario (CAEIP) del CatSalut Comissió d'Avaluació Econòmica i Impacte Pressupostari (CAEIP) Barcelona [consultado 23 May 2012). Disponible en
    • Comisión de Evaluación Económica e Impacto Presupuestario (CAEIP) del CatSalut Dictamen sobre las recomendaciones farmacológicas en base a criterios de coste-efectividad del trastorno por el déficit de atención e hiperactividad en Cataluña 2012 Comissió d'Avaluació Econòmica i Impacte Pressupostari (CAEIP) Barcelona [consultado 23 May 2012). Disponible en: http://www10.gencat. cat/catsalut/archivos/farmacia/CAEIP/tdah-dictamen-es.pdf
    • (2012) Dictamen Sobre Las Recomendaciones Farmacológicas en Base A Criterios de Coste-efectividad Del Trastorno Por El Déficit de Atención e Hiperactividad en Cataluña


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.